This activity will provide pharmacists, residents, and pharmacy technicians with information in order to help determine how to provide safe and efficacious therapy options for the pediatric patients with pulmonary hypertension. The most recent guidelines for pediatric pulmonary hypertension are recommendations from the American Heart Association and American Thoracic Society, but there have not been any updates since 2015. Traditionally, nitric oxide has been the gold standard of therapy. However, this is a costly inhalation therapy and provides potential complications to patients that require treatment therapy in the outpatient setting. With newer primary literature emerging, prostacyclins have been shown to be more cost effective compared to nitric oxide and have some newer studies demonstrating that it can be used as an alternative therapy or when refractory to nitric oxide therapy. This presentation will review primary literature behind the use of prostacyclin therapy for pediatric pulmonary hypertension and help identify its place in practice.